Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Nicolas Girard, Jair Bar, Pilar Garrido, +20

Journal of Thoracic Oncology

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

Israel Cañadas, Federico Rojo, Álvaro Taus, +12

Clinical Cancer Research

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Manuel Hidalgo, Maria Martinez‐García, Christophe Le Tourneau, +20

Clinical Cancer Research

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Carlos Gomez‐Roca, Philippe A. Cassier, Dmitriy Zamarin, +26

Journal for ImmunoTherapy of Cancer

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Max Hardy-Werbin, Pedro Rocha, Oriol Arpí, +13

OncoImmunology

Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples

David Casadevall, Sergi Clavé, Álvaro Taus, +8

Clinical Lung Cancer

Cancer ImmunosurveillanceMalignant DiseaseMedicineImmunologyTumor Immunity +8

First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

Didier Meulendijks, Wolfgang Jacob, Maria Martinez‐García, +19

Clinical Cancer Research

Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer

Ramón Palmero, Álvaro Taus, Santiago Viteri, +14

JCO Precision Oncology

MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC)

David Casadevall, Javier Gimeno, Sergi Clavé, +11

Oncotarget

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

Jonathan W. Goldman, Julien Mazières, Fabrice Barlési, +21

Frontiers in Oncology